LDC000067
LDC000067 Basic information
- Product Name:
- LDC000067
- Synonyms:
-
- LDC000067
- LDC 067
- LDC067
- LDC-067
- (3-(6-(2-Methoxyphenyl)pyrimidin-4-ylamino)phenyl)methanesulfonamide
- 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-benzenemethanesulfonamide
- LDC067;LDC 000067;LDC-000067;LDC 067;LDC-067
- CS-1535
- CAS:
- 1073485-20-7
- MF:
- C18H18N4O3S
- MW:
- 370.43
- Product Categories:
-
- Inhibitors
- API
- Mol File:
- 1073485-20-7.mol
LDC000067 Chemical Properties
- Boiling point:
- 604.1±65.0 °C(Predicted)
- Density
- 1.360±0.06 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2–8 °C
- solubility
- insoluble in H2O; insoluble in EtOH; ≥18.52 mg/mL in DMSO
- form
- Powder
- pka
- 10.27±0.60(Predicted)
- color
- White to off-white
LDC000067 Usage And Synthesis
Biological Activity
ldc000067 (ldc067) is a novel specific inhibitor of cdk9 with ic50 value of 44 ± 10 nm [1].cyclin-dependent kinase 9 (cdk9) is a cyclin-dependent kinase. cdk9 and cyclin t form the positive transcription elongation factor b (p-tefb) complex for rna polymerase ii and functions by phosphorylating the c-terminal domain of the largest subunit of rna polymerase ii [1].ldc000067 (ldc067) is a novel and highly specific cdk9 inhibitor. ldc000067 exhibited selectivity for cdk9 over other cdks in the range of 55-fold (vs. cdk2) to over 230-fold (vs. cdk6 and cdk7). ldc067 also inhibited transcription in a dose-dependent and atp-competitive manner. in whole cells, ldc000067 induced the tumor suppressor protein p53 activation and apoptosis. ldc000067 also selectively reduced short-lived mrnas, including those that encode regulators of apoptosis and proliferation such as myc and mcl1 [1].
in vitro
LDC000067 reduces Ser2-P in mESCs, induces p53 activation, and leads to apoptosis. In addition, LDC067 also dose-dependently inhibited the de novo RNA synthesis of P-TEFb-dependent cellular genes.
target
Target | Value |
CDK9 (Cell-free assay) | 44 nM |
CDK2 (Cell-free assay) | 2.441 μM |
storage
Store at -20°C
References
[1]. albert tk, rigault c, eickhoff j, et al. characterization of molecular and cellular functions of the cyclin-dependent kinase cdk9 using a novel specific inhibitor. br j pharmacol, 2014, 171(1): 55-68.
LDC000067Supplier
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 13661494087 18964793018
- sales@mof-chemicals.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- +1 (866) 930-6790
- info@adooq.com
- Tel
- 18149758185 18149758185
- sales-cpd@caerulumpharma.com